NsGene
closedNsGene develops products for the treatment of neurological, alzheimer’s, and parkinson's disease and sensorineural hearing loss.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD32—48m (Dealroom.co estimates May 2005.)
Company register number 21479195
Ballerup Capital Region of Denmark (HQ)
Financials
Estimates*
DKK | 2013 | 2014 | 2015 |
---|---|---|---|
Revenues | 11.8m | 9.2m | 12.0m |
% growth | - | (22 %) | 31 % |
Profit | 4.9m | 8.4m | 11.6m |
% profit margin | 41 % | 92 % | 97 % |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$5.1m | Early VC | ||
N/A | $550k | Grant | |
Total Funding | AUD8.8m |
Related Content
Recent News about NsGene
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.